Enfusion, which produces Cloud-based investment management software, wrapped its IPO, selling 15.322 million shares at $17 per share, the high end of its announced price range.
Shares of Enfusion will begin trading on the NYSE later today under the ticker symbol ENFN, but shares are available for limit orders on Robinhood and other platforms.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $10.76 |
|---|---|
| 52-week range | $7.83 - $11.80 |
| 50-day moving average | $11.09 |
| 200-day moving average | $9.90 |
| Wall St. target price | $11.25 |
| PE ratio | 358.6667 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.03 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $10.76 from 2025-04-17
| 1 week (2025-05-01) | N/A |
|---|---|
| 1 month (2025-04-11) | -0.46% |
| 3 months (2025-02-12) | -2.71% |
| 6 months (2024-11-12) | 13.26% |
| 1 year (2024-05-10) | 18.90% |
|---|---|
| 2 years (2023-05-11) | 32.19% |
| 3 years (2022-05-11) | 6.64% |
| 5 years (2020-05-08) | N/A |
Valuing Enfusion stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Enfusion's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Enfusion's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 359x. In other words, Enfusion shares trade at around 359x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Enfusion's P/E ratio is best considered in relation to those of others within the software - application industry or those of similar companies.
Enfusion's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $12.7 million.
The EBITDA is a measure of a Enfusion's overall financial performance and is widely used to measure a its profitability.
To put Enfusion's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $201.6 million |
|---|---|
| Operating margin TTM | 2.99% |
| Gross profit TTM | $136.7 million |
| Return on assets TTM | 3.05% |
| Return on equity TTM | 4.42% |
| Profit margin | 1.4% |
| Book value | $0.77 |
| Market Capitalization | $1 billion |
TTM: trailing 12 months
We're not expecting Enfusion to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Enfusion's shares have ranged in value from as little as $7.83 up to $11.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Enfusion's is 0.928. This would suggest that Enfusion's shares are less volatile than average (for this exchange).
To put Enfusion's beta into context you can compare it against those of similar companies.
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also provides Accounting/General Ledger System, a proper double-entry ledger that automates the posting of general ledger journal entries for all cash and securities transactions for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois. .
We dug through 60 years of Berkshire Hathaway annual shareholder letters to bring you 9 lessons from Warren Buffett: “The Oracle of Omaha.”
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.